Advantages: To describe the effect of intravitreal ranibizumab for the treatment of choroidal neovascularisation and macular edema secondary to Best’s vitelliform macular dystrophy. Methods: A 38-year-old Asian woman with confirmed Best’s disease presented with decreased visual acuity (VA) due to secondary choroidal neovascularisation and macular edema. She was treated with a single intravitreal injection of ranibizumab (Lucentis, 0.5...

Read More